$1.75
0.010.57%
At Close: -
$1.78
0.031.71%
After Hours: 7:11 PM EDT
15 minutes delayed
Comments
Loading...
Plus Therapeutics
PSTVNASDAQ
Plus Therapeutics (NASDAQ:PSTV) Stock, Analyst Ratings, Price Targets, Forecasts
Plus Therapeutics Inc has a consensus price target of $8.33 based on the ratings of 3 analysts. The high is $12 issued by Maxim Group on May 3, 2023. The low is $5 issued by JonesTrading on October 7, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on August 15, 2023, August 14, 2023, and June 30, 2023, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 349.44% upside for Plus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Plus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 08/15/2023 | Buy Now | 349.44% | HC Wainwright & Co. | Sean Lee | → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 349.44% | HC Wainwright & Co. | Sean Lee | → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 349.44% | HC Wainwright & Co. | Sean Lee | $3.5 → $8 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 574.16% | Maxim Group | Jason McCarthy | $30 → $12 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 96.63% | HC Wainwright & Co. | Sean Lee | → $52.5 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 96.63% | HC Wainwright & Co. | Sean Lee | → $52.5 | Reiterates | → Buy | Get Alert |
| 10/07/2022 | Buy Now | 180.9% | JonesTrading | Justin Walsh | → $75 | Initiates | → Buy | Get Alert |
| 07/22/2022 | Buy Now | 96.63% | HC Wainwright & Co. | Sean Lee | $105 → $52.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Plus Therapeutics (PSTV) stock?
The latest price target for Plus Therapeutics (NASDAQ:PSTV) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $8.00 expecting PSTV to rise to within 12 months (a possible 349.44% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Plus Therapeutics (PSTV)?
The latest analyst rating for Plus Therapeutics (NASDAQ:PSTV) was provided by HC Wainwright & Co., and Plus Therapeutics reiterated their buy rating.
When was the last upgrade for Plus Therapeutics (PSTV)?
There is no last upgrade for Plus Therapeutics
When was the last downgrade for Plus Therapeutics (PSTV)?
There is no last downgrade for Plus Therapeutics.
When is the next analyst rating going to be posted or updated for Plus Therapeutics (PSTV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Plus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Plus Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Plus Therapeutics (PSTV) correct?
While ratings are subjective and will change, the latest Plus Therapeutics (PSTV) rating was a reiterated with a price target of $0.00 to $8.00. The current price Plus Therapeutics (PSTV) is trading at is $1.78, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.